Stellar Biotechnologies stock spiked June 21 after the company announced the completion of a third party research study and quality analysis of its products. The study showed that molecular structures of its Keyhole Limpet hemocyanin, or KLH proteins, were highly consistent in molecular structure from batch to batch, a trait that helps enhance immune responses…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
